| P50 | author | Rainer Spanbroek | Q128792584 |
| P2093 | author name string | Ignacio Rubio | |
| | Karlheinz Friedrich | |
| | Martin Augsten | |
| | Anika Böttcher | |
| P2860 | cites work | Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling | Q24293500 |
| | Ras/Rap effector specificity determined by charge reversal | Q24315941 |
| | Tumor microenvironment and neurofibromatosis type I: connecting the GAPs | Q24654681 |
| | The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation | Q24655603 |
| | In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction | Q27677868 |
| | Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization | Q27678182 |
| | Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation | Q27678948 |
| | Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? | Q27690752 |
| | Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo | Q27852093 |
| | Live-cell imaging of endogenous Ras-GTP shows predominant Ras activation at the plasma membrane and in the nucleus in Saccharomyces cerevisiae. | Q27938856 |
| | A positive-feedback-based bistable 'memory module' that governs a cell fate decision | Q28188515 |
| | Targeting RAS signalling pathways in cancer therapy | Q28201363 |
| | Raf kinases in cancer-roles and therapeutic opportunities | Q28237793 |
| | RAS oncogenes: weaving a tumorigenic web | Q28250360 |
| | Ras signalling is required for inactivation of the tumour suppressor pRb cell-cycle control protein | Q28256250 |
| | Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate | Q28576088 |
| | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 |
| | Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 |
| | RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 |
| | The RAF proteins take centre stage | Q29620153 |
| | A comprehensive survey of Ras mutations in cancer | Q30416821 |
| | Network analysis of oncogenic Ras activation in cancer | Q30444797 |
| | An alternative method to amplify RNA without loss of signal conservation for expression analysis with a proteinase DNA microarray in the ArrayTube format | Q33246508 |
| | Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro | Q33292215 |
| | Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects | Q34136641 |
| | Regulation and Function of the RasGRP Family of Ras Activators in Blood Cells | Q35083742 |
| | Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy | Q35200298 |
| | Farnesyltransferase inhibitors as anticancer agents: current status. | Q35648789 |
| | Clinical studies of antisense oligonucleotides for cancer therapy. | Q35890990 |
| | Ras trafficking, localization and compartmentalized signalling | Q36043314 |
| | Targeting oncogenic Ras signaling in hematologic malignancies | Q36352506 |
| | Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling | Q36640274 |
| | Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function | Q36950248 |
| | Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells | Q37261134 |
| | Ras signaling and therapies | Q37548931 |
| | Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function | Q37720942 |
| | Partner exchange: protein-protein interactions in the Raf pathway | Q37771734 |
| | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 |
| | Regulating the regulator: post-translational modification of RAS | Q37970568 |
| | RAS/RAF/MEK inhibitors in oncology | Q37976864 |
| | Targeting MET in cancer: rationale and progress | Q37978193 |
| | Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase | Q38298684 |
| | Leukemia inhibitory factor triggers activation of signal transducer and activator of transcription 3, proliferation, invasiveness, and altered protease expression in choriocarcinoma cells | Q38321713 |
| | Nox4-derived H2O2 mediates endoplasmic reticulum signaling through local Ras activation | Q38344102 |
| | Interfering with RAS–effector protein interactions prevent RAS-dependent tumour initiation and causes stop–start control of cancer growth | Q39659284 |
| | TCR-induced activation of Ras proceeds at the plasma membrane and requires palmitoylation of N-Ras. | Q39666904 |
| | Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling | Q39773899 |
| | Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D). | Q39835843 |
| | SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients | Q40038376 |
| | Live-cell imaging of endogenous Ras-GTP illustrates predominant Ras activation at the plasma membrane | Q40352237 |
| | Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells | Q40762471 |
| | Mutant ras epitopes as targets for cancer vaccines | Q40973641 |
| | Discrimination of amino acids mediating Ras binding from noninteracting residues affecting raf activation by double mutant analysis | Q41075527 |
| | ETS sites in the promoters of the matrix metalloproteinases collagenase (MMP-1) and stromelysin (MMP-3) are auxiliary elements that regulate basal and phorbol-induced transcription | Q41135869 |
| | Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. | Q41554332 |
| | Activation of the c-Met receptor complex in fibroblasts drives invasive cell behavior by signaling through transcription factor STAT3. | Q42815733 |
| | Desensitization of Ras Activation by a Feedback Disassociation of the SOS-Grb2 Complex | Q42824495 |
| | The minimal fragments of c-Raf-1 and NF1 that can suppress v-Ha-Ras-induced malignant phenotype. | Q42831995 |
| | Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction | Q42847300 |
| | Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells | Q45348110 |
| | Transformation of NIH3T3 fibroblasts by an expression vector for the human epidermal growth factor precursor. | Q53505878 |
| | Inhibition of cell surface ruffling and fluid-phase pinocytosis by microinjection of anti-ras antibodies into living cells. | Q53532363 |
| | Requirement of Ras-GTP-Raf Complexes for Activation of Raf-1 by Protein Kinase C | Q57979874 |
| | A Harvey-ras responsive transcription element is also responsive to a tumour-promoter and to serum | Q58985113 |
| | Quantitative structure-activity analysis correlating Ras/Raf interaction in vitro to Raf activation in vivo | Q71011188 |
| | Endogenous c-N-Ras provides a steady-state anti-apoptotic signal | Q73703903 |
| | Recognizing and defining true Ras binding domains I: biochemical analysis | Q81643533 |
| P304 | page(s) | 1 | |
| P577 | publication date | 2014-01-02 | |
| P1433 | published in | Cell Communication and Signaling | Q1254390 |
| P1476 | title | Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains | |
| P478 | volume | 12 | |